EUVIMEDOpdag EUVIMED
Crossref

Screening and Predictive Biomarkers for Down Syndrome Through Amniotic Fluid Metabolomics

Li-Chao Zhang, Xiang-Chun Yang, Yong-Hong Jiang, Zhen Yang iD, Lu-Lu Yan, Yu-Xin Zhang, Qiong Li, Li-Yun Tian, Juan Cao, Ying Zhou, Shan-Shan Wu, Dan-Yan Zhuang and 2 more

Prenatal Diagnosis · 2025

DOI: 10.1002/pd.6693 ↗

At a glance

Journal article in Prenatal Diagnosis, 2025. Written by Li-Chao Zhang and 13 co-authors. Institution: The Central Laboratory of Birth Defects Prevention and Control, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China. Major MEDLINE topics: Down Syndrome, Amniotic Fluid, Metabolomics, Biomarkers. Cited 2 times so far (Crossref); 31 references. Funded by: Ningbo Science and Technology Project, Science and Technology Development Program of Ningbo, Ningbo Top Medical and Health Research Program.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Down syndrome (DS) is a congenital disorder caused by the presence of an extra copy of all or part of chromosome 21. It is characterized by significant intellectual disability, distinct facial features, and growth and developmental challenges. The utilization of metabolomics to analyze specific metabolic markers in maternal amniotic fluid may provide innovative tools and screening methods for investigating the early pathophysiology of trisomy 21 at the functional level.

Methods

Amniotic fluid samples were obtained via amniocentesis from 57 pregnancies with DS and 55 control pregnancies between 17 3/7 and 24 0/7 weeks of gestation. The targeted metabolomics focused on 34 organic acids, 17 amino acids, and 5 acylcarnitine metabolites. The untargeted metabolomics analysis concentrated on lipid profiles and included 602 metabolites that met quality control standards. Principal Component Analysis, Orthogonal Partial Least Squares Discriminant Analysis (OPLS‐DA), and false discovery rate (FDR) adjustments were applied. MetaboAnalystR 5.0 was used to perform the metabolic pathway analysis on the identified differential metabolites.

Results

Fifty differential metabolites, including L‐glutamine, eight organic acids, and 41 lipids, were significantly altered in DS based on three criteria: VIP > 1 in the OPLS‐DA model, FDR‐adjusted p ‐value < 0.05, and |log 2 FC| > log 2 (1.5) from a volcano plot of all detected metabolites. An analysis of 212 differential metabolites, selected from both targeted and untargeted approaches (VIP > 1 in the OPLS‐DA model and FDR‐adjusted p ‐value < 0.05), revealed significant changes in nine metabolic pathways. Fourteen key metabolites were identified to establish a screening model for DS, achieving an area under the curve of 1.00.

Conclusions

Our results underscore the potential of metabolomics approaches in identifying concise and reliable biomarker combinations that demonstrate promising screening performance in DS.

Subjects

MeSH terms (MEDLINE)

Down SyndromeAmniotic FluidMetabolomicsBiomarkersHumansFemalePregnancyAdultCase-Control StudiesAmniocentesisPrenatal Diagnosis

Substances

Biomarkers

Authors and institutions

  • The Central Laboratory of Birth Defects Prevention and Control, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China.
  • Ningbo Key Laboratory for the Prevention and Treatment of Embryogenic Diseases, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China.
  • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China.
  • Clin Lab, BGI Genomics, Shanghai, China.
  • Prenatal and Neonatal Screening Center, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China.
  • Fetal Medicine Centre, The Affiliated Women and Children's Hospital of Ningbo University, Ningbo, China.

ORCID profiles: Zhen Yang, Hai-Bo Li

Funding

  • Ningbo Science and Technology Project
  • Science and Technology Development Program of Ningbo
  • Ningbo Top Medical and Health Research Program
  • Key Technology Breakthrough Program of Ningbo Sci-Tech Innovation YONGJIANG 2035

Cite

APA

Zhang, L. C., Yang, X. C., Jiang, Y. H., Yang, Z., Yan, L. L., Zhang, Y. X., Li, Q., Tian, L. Y., Cao, J., Zhou, Y., Wu, S. S., Zhuang, D. Y., Chen, C. S., & Li, H. B. (2025). Screening and Predictive Biomarkers for Down Syndrome Through Amniotic Fluid Metabolomics. Prenatal Diagnosis. https://doi.org/10.1002/pd.6693

Vancouver

Zhang LC, Yang XC, Jiang YH, Yang Z, Yan LL, Zhang YX, et al. Screening and Predictive Biomarkers for Down Syndrome Through Amniotic Fluid Metabolomics. Prenatal Diagnosis. 2025. doi:10.1002/pd.6693

BibTeX
@article{Zhang2025,
  author = {Zhang, Li-Chao and Yang, Xiang-Chun and Jiang, Yong-Hong and Yang, Zhen and Yan, Lu-Lu and Zhang, Yu-Xin and Li, Qiong and Tian, Li-Yun and Cao, Juan and Zhou, Ying and Wu, Shan-Shan and Zhuang, Dan-Yan and Chen, Chang-Shui and Li, Hai-Bo},
  title = {Screening and Predictive Biomarkers for Down Syndrome Through Amniotic Fluid Metabolomics},
  journal = {Prenatal Diagnosis},
  year = {2025},
  doi = {10.1002/pd.6693}
}
Start for free →